natgillin/translations-raw huggingface dataset:
Fluoroquinolone antibiotics, including Quofenix, may cause levels of glucose in the blood to rise too high or fall too low.
Fluorokinolonski antibiotici, uključujući Quofenix, mogu uzrokovati razine glukoze u krvi koje su ili previsoke ili preniske.
This medicine contains 39 mg of sodium (main component of cooking salt) in each tablet.
Ovaj lijek sadrži 39 mg natrija (glavni sastojak kuhinjske soli) u jednoj tableti.
Glucuronidation of delafloxacin is the primary metabolic pathway with oxidative metabolism representing <1% of an administered dose.
Glukuronidacija delafloksacina je primarni metabolički put, a oksidativni metabolizam prolazi <1%
In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.
U slučajevima iznenadne boli u abdomenu, prsištu ili leđima, bolesnike je potrebno savjetovati da se odmah obrate liječniku u hitnoj medicinskoj službi.
In diabetic patients, careful monitoring of blood glucose is recommended.
U bolesnika s dijabetesom preporučuje se pažljivo praćenje razine glukoze u krvi.
Some adverse drug reactions (e.g. dizziness, headache, visual disorders) may impair the patient's ability to concentrate and react, and therefore may constitute a risk in situations where the patient operates an automobile or machinery or engages in other activities requiring mental alertness and coordination.
Neke nuspojave (npr. omaglica, glavobolja, poremećaji vida) mogu oslabiti bolesnikovu sposobnost koncentracije i reagiranja te, stoga, predstavljaju rizik u situacijama kada bolesnik upravlja vozilima ili strojevima ili je uključen u druge aktivnosti koje zahtijevaju mentalnu pozornost i koordinaciju.
Millmount Healthcare Block-7, City North Business Campus, Stamullen, Co. Meath Ireland or
MillMount Healthcare Block-7, City North Business Campus, Stamullen, Co.
MillMount Healthcare Block-7, City North Business Campus, Stamullen, Co. Meath Ireland or
Millmount Healthcare Block-7, City North Business Campus, Stamullen, Co.
Cases of bullous skin reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported with other fluoroquinolones.
Zabilježeni su slučajevi buloznih kožnih reakcija poput Stevens-Johnsonovog sindroma ili toksične epidermalne nekrolize tijekom liječenja drugim fluorokinolonima.
Quofenix is contraindicated in children and adolescents (see section 4.3).
Quofenix je kontraindiciran u djece i adolescenata (vidjeti dio 4.3).
Do not take any medicine to treat your diarrhoea without first checking with your doctor.
Ne uzimajte nikakve lijekove za liječenje proljeva a da se prethodno niste posavjetovali s Vašim liječnikom.
No adverse effects were seen in rats at exposures about 2-fold higher than humans, or in dogs at exposures approximately equal to humans.
Nisu uočeni štetni učinci kod štakora pri izloženosti oko 2 puta većoj nego kod ljudi, ili kod pasa pri izloženosti približno istoj kao kod ljudi.
Pack sizes of 10 x1, 20 x1, 30 x1, 50 x1, 60 x1 or 100 x1 tablets.
Veličine pakiranja: 10 x 1, 20 x 1, 30 x 1, 50 x 1, 60 x 1 ili 100 x 1 tableta.
• Cold sweat
• hladni znoj
Effect of delafloxacin on other medicinal products
Djelovanje delafloksacina na druge lijekove
If you might become pregnant you have to use effective contraception during treatment with Quofenix.
Ako možete zatrudnjeti, tijekom liječenja Quofenixom morate koristiti učinkovitu kontracepciju.
Oral administration of delafloxacin with antacids containing aluminium or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as didanosine buffered tablets for oral suspension or the paediatric powder for oral solution, may substantially interfere with the absorption of delafloxacin, resulting in systemic concentrations considerably lower than desired.
Peroralna primjena delafloksacina s antacidima koji sadrže aluminij ili magnezij, sa sukralfatom, s metalnim kationima poput željeza ili s multivitaminima koji sadrže željezo ili cink, ili s formulacijama koje sadrže dvovalentne i trovalentne katione poput didanozina u obliku puferiranih tableta za oralnu suspenziju ili pedijatrijskog praška za oralnu otopinu, mogu bitno interferirati s apsorpcijom delafloksacina, što rezultira značajno nižim sistemskim koncentracijama od željenih.
A. Menarini Portugal - Farmacêutica, S.A. Tel: +351 210 935 500
Menarini Portugal - Farmacêutica, S.A. Tel: +351 210 935 500
Dosing in patients with severe renal impairment (CrCl of <30 mL/min) should be decreased to 200 mg intravenously every 12 hours; alternatively patients should receive 450 mg delafloxacin orally every 12 hours (see section 4.4 and 5.2).
(CrCl <30 ml/min) treba smanjiti na 200 mg intravenski svakih 12 sati; alternativno bolesnici trebaju dobiti 450 mg delafloksacina peroralno svakih 12 sati (vidjeti dijelove 4.4 i 5.2).
MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE
PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE
As delafloxacin is excreted in milk, severe toxicity was observed in newborn rats during lactation when mothers were treated during pregnancy and lactation with delafloxacin at a dose producing a systemic exposure about 5-fold higher than observed in humans.
Kako se delafloksacin izlučuje u mlijeko, primijećena je teška toksičnost tijekom dojenja novorođenih štakora kada su majke tijekom trudnoće i dojenja bile liječene delafloksacinom u dozi koja je proizvela sistemsku izloženost oko 5 puta veću nego u ljudi.
Quofenix is an antibiotic that contains the active substance delafloxacin.
Quofenix je antibiotik koji sadrži djelatnu tvar delafloksacin.
Nonclinical studies conducted with delafloxacin in rats do not indicate harmful effects with respect to fertility or reproductive performance (see section 5.3).
Neklinička ispitivanja provedena s delafloksacinom u štakora ne ukazuju na štetne učinke na plodnost ili sposobnost reprodukcije (vidjeti dio 5.3).
You will be given one infusion of Quofenix, containing 300 mg of the medicine, twice a day between 5 and 14 days at the discretion of your doctor.
Primiti ćete infuziju lijeka Quofenix, koja sadrži 300 mg lijeka, dvaput dnevno, tijekom 5 do 14 dana,
• You may have a severe skin reaction such as blistering or lesion.
• ako imate teške kožne reakcije poput stvaranja mjehura ili rana.
In embryo-fetal development studies carried out in rats and rabbits, delafloxacin was devoid of teratogenic effects but induced foetal growth retardation and ossification delays at levels of dose producing maternal toxicity.
U ispitivanjima embriofetalnog razvoja provedenim na štakorima i kunićima, delafloksacin nije imao teratogene učinke, ali je inducirao retardaciju fetalnog rasta i kašnjenje osifikacije, pri razinama doze koja je dovodila do maternalne toksičnosti.
• Blood in urine
• krv u mokraći
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, tell your doctor before you are taking this medicine.
Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku za savjet prije nego uzmete ovaj lijek.
Therefore, no dosage adjustment is necessary.
Stoga nije potrebna prilagodba doze.
Treatment of these patients with delafloxacin should only be initiated in the absence of alternative treatment options and after careful benefit/risk assessment (see also section 4.3).
Liječenje tih bolesnika delafloksacinom smije se započeti samo ako nema drugih terapijskih mogućnosti te nakon pažljive procjene omjera koristi i rizika (vidjeti također dio 4.3).
It is available in perforated unit dose blister pack which contains blisters of 10x1 tablets into pack size of 10,20,30,50, 60 or 100 tablets per carton.
Dostupan je u pakiranju s perforiranim blisterima s jediničnom dozom koje sadrži blistere s 10x1 tabletom, pakirane u kutije sa 10, 20, 30, 50, 60 ili 100 tableta.
If this happens, stop taking Quofenix and inform your doctor immediately in order to prevent the development of potentially irreversible condition.
Ako se to dogodi, prestanite uzimati Quofenix i odmah obavijestite svog liječnika kako bi se spriječio razvoj potencijalno nepopravljivih oštećenja.
• Prepare the required dose for intravenous infusion by withdrawing the volume of 12 ml for Quofenix 300 mg or 8 ml for Quofenix 200 mg from the reconstituted vial.
• Pripremiti potrebnu dozu za intravensku infuziju izvlačeći volumen od 12 ml iz rekonstituirane bočice za Quofenix 300 mg ili 8 ml za Quofenix 200 mg.
In repeat dose toxicity studies in rats and dogs, gastrointestinal effects were the main findings: these included dilated cecum (oral only), abnormal stool, and decreased food intake and / or body weight in rats, and emesis, salivation and abnormal stool / diarrhoea in dogs.
U ispitivanjima toksičnosti ponovljenih doza na štakorima i psima, glavni nalazi bili su gastrointestinalni učinci, uključujući dilatirani cekum (samo peroralno), abnormalnu stolicu, smanjen unos hrane i/ili tjelesnu težinu u štakora, te emezu, salivaciju i abnormalnu stolicu / proljev u pasa.
Long-term carcinogenicity studies have not been conducted with delafloxacin.
Nisu provedena dugotrajna ispitivanja kancerogenosti s delafloksacinom.
Tell your doctor or nurse immediately if you are concerned that you may have been given too much Quofenix.
Odmah obavijestite Vašeg liječnika ili medicinsku sestru ako se brinete da ste možda primili previše lijeka Quofenix.
• You have diabetes.
• ako imate dijabetes.
At the first sign of tendinitis (e.g. painful swelling, inflammation) the treatment with delafloxacin should be discontinued and alternative treatment should be considered.
Kod prvog znaka tendinitisa (npr. bolnog oticanja, upale) treba prekinuti liječenje delafloksacinom i razmotriti drugu mogućnost liječenja.
Based on in vitro data on metabolising enzymes and transporters delafloxacin possesses a low potential to alter the disposition of other medicinal products (see section 5.2).
Na temelju podataka in vitro o učincima na metabolizirajuće enzime i transportere, delafloksacin ima mali potencijal za mijenjanje dispozicije drugih lijekova (vidjeti dio 5.2).
The fAUC24/MIC ratio, as for other quinolone antibiotics, resulted in the pharmacokinetic/ pharmacodynamic parameter most closely associated with the efficacy of delafloxacin.
Omjer fAUC24/MIK se, kao i za druge kinolonske antibiotike, pokazao farmakokinetičkim/ farmakodinamičkim parametrom koji je bio najbolje povezan s djelotvornošću delafloksacina.
Cases of hypoglycaemic coma have been reported.
Prijavljeni su slučajevi hipoglikemijske kome.
No clinical trials have been conducted with delafloxacin in paediatric patients.
Nisu provedena klinička ispitivanja s delafloksacinom u pedijatrijskih bolesnika.
As per fluoroquinolone class patients aged over 60 years are at increased risk for developing severe tendon disorders including tendon rupture (see sections 4.4 and
Kao i za druge lijekove iz skupine fluorokinolona, bolesnici stariji od 60 godina imaju veći rizik pojave teških poremećaja tetiva uključujući rupturu tetive (vidjeti dijelove 4.4 i 5.2).
It is unknown whether delafloxacin/metabolites are excreted in human milk.
Nije poznato izlučuju li se delafloksacin/metaboliti u majčino mlijeko.
This medicinal product contains 39 mg sodium per tablet, equivalent to 2% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
Ovaj lijek sadrži 39 mg natrija po tableti, što odgovara 2% maksimalnog dnevnog unosa od 2 g natrija prema preporukama SZO za odraslu osobu.
At the first sign of pain or inflammation of a tendon (for example in your ankle, wrist, elbow, shoulder or knee), stop taking Quofenix, contact your doctor and rest the painful area.
Kod prvog znaka boli ili upale tetive (na primjer, u gležnju, zapešću, laktu, ramenu ili koljenu), prestanite uzimati Quofenix, obratite se liječniku i pazite da bolno područje miruje.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON (TABLETS)
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKA KUTIJA (TABLETE)
Streptococcus oralis, Streptococcus mitis, and Streptococcus sanguinis)
Streptococcus oralis, Streptococcus mitis i Streptococcus sanguinis)
• Streptococcus mitis group (including Streptococcus cristatus, Streptococcus gordonii,
• Skupina Streptococcus mitis (uključujući Streptococcus cristatus, Streptococcus gordonii,
The vial contains light yellow to tan cake powder.
Bočica sadrži prašak svijetlo žute boje do boje pudera.
Paediatric population Quofenix is contraindicated in children and adolescents (see section 4.3).
Pedijatrijska populacija Quofenix je kontraindiciran u djece i adolescenata (vidjeti dio 4.3).
Delafloxacin pharmacokinetic is comparable in patients with ABSSSI and healthy volunteers.
Farmakokinetika delafloksacina usporediva je u bolesnika s ABSSSI-om s farmakokinetikom u zdravih dobrovoljaca.
• Blood test alteration related to kidney or liver function (blood alkaline phosphatase increased,
• promjene krvnih nalaza povezanih s funkcijom bubrega ili jetre (povišena alkalna fosfataza u krvi, sniženi albumin u krvi)
The half-life of IV delafloxacin is approximately 10 hours.
Poluvijek intravenskog delafloksacina je približno 10 sati.
• Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus)
• Skupina Streptococcus anginosus (uključujući Streptococcus anginosus, Streptococcus intermedius i Streptococcus constellatus)
The radioactivity recovered from faeces is unchanged delafloxacin.
Radioaktivnost izlučena u fecesu odnosi se na nepromijenjeni delafloksacin.
Chelation active substance: antacids, sucralfate, metal cations, multivitamins There are no data concerning an interaction of intravenous delafloxacin with multivitamins, didanosine, or metal cations.
Djelatne tvari koje keliraju: antacidi, sukralfat, metalni kationi, multivitamini Nema podataka o interakciji intravenskog delafloksacina s multivitaminima, didanozinom ili metalnim kationima.
Effect of other medicinal products on delafloxacin
Djelovanje drugih lijekova na delafloksacin
If these reactions occur in patients receiving delafloxacin, delafloxacin should be discontinued immediately and appropriate measures should be instituted.
Ako se ove reakcije pojave u bolesnika koji primaju delafloksacin, odmah treba prekinuti primjenu delafloksacina i poduzeti odgovarajuće mjere.
Patients should be advised to contact their doctor immediately prior to continuing treatment if skin and/or mucosal reactions occur.
Bolesnicima se mora savjetovati da se prije nastavka liječenja odmah jave svom liječniku ako se pojave kožne reakcije i/ili reakcije na sluznicama.
Fluoroquinolones may also cause CNS reactions of nervousness, agitation, insomnia, anxiety, nightmares, paranoia, dizziness, confusion, tremors, hallucinations, depression, and suicidal thoughts or acts.
Fluorokinoloni također mogu uzrokovati reakcije središnjeg živčanog sustava kao što su nervoza, agitacija, nesanica, anksioznost, noćne more, paranoja, omaglica, konfuzija, tremori,
Corticosteroids should not be used if signs of tendinopathy occur (see section 4.8).
Ako se pojave znakovi tendinopatije, ne smiju se primjenjivati kortikosteroidi (vidjeti dio 4.8).
Delafloxacin does not induce CYP1A2, CYP2B6, CYP2C9, CYP2C8, CYP2C19 or CYP3A4/5.
Delafloksacin ne inducira CYP1A2, CYP2B6, CYP2C9, CYP2C8, CYP2C19 ili CYP3A4/5.
Pharmacokinetic parameters are not altered in obese patients (BMI ≥ 30 kg/m2).
Farmakokinetički parametri nisu promijenjeni u pretilih bolesnika (ITM ≥ 30 kg/m2).
The highest daily intravenous dose administered in clinical studies was 1200 mg; the patients who receive this dose did not have any adverse drug reactions or notable clinical laboratory test findings during the study.
Najviša dnevna intravenska doza primijenjena u kliničkim ispitivanjima bila je 1200 mg; bolesnici koji su primili tu dozu tijekom ispitivanja nisu imali niti jednu nuspojavu ili značajan nalaz laboratorijskih pretraga.
If a common intravenous line is being used to administer other medicinal products in addition to Quofenix the line should be flushed before and after each Quofenix infusion with sodium chloride 9 mg/ml (0.9%) solution for injection or D5W.
Ako se koristi ista intravenska linija za primjenu drugih lijekova uz Quofenix, linija se treba isprati prije i nakon svake infuzije Quofenixa otopinom natrijeva klorida za injekcije od 9 mg/ml (0,9%) ili sa D5W.
The half-life of oral delafloxacin is approximately 14 hours.
Poluvijek peroralnog delafloksacina je približno 14 sati.
Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for delafloxacin are as follows:
Granične vrijednosti minimalne inhibitorne koncentracije (MIK) koje je odredio Europski odbor za testiranje osjetljivosti na antimikrobna sredstva (engl.
There is limited experience in patients aged > 75 years.
Ograničeno je iskustvo u bolesnika u dobi
Clostridioides difficile-associated disease has been reported in users of nearly all systemic antibacterial medicinal products, with severity ranging from mild diarrhoea to fatal colitis.
Bolest povezana s Clostridioides difficile prijavljena je kod korisnika gotovo svih sistemskih antibakterijskih lijekova, te mogu varirati u težini od blagog proljeva do kolitisa sa smrtnim ishodom.
Patients with known hypersensitivity to delafloxacin or other fluoroquinolones must not take Quofenix (see section 4.3).
Bolesnici s poznatom preosjetljivošću na delafloksacin ili druge fluorokinolone ne smiju uzimati Quofenix (vidjeti dio 4.3).
If you take more Quofenix than you should
Ako uzmete više Quofenixa nego što ste trebali
Pack-size: 10 vials.
Pakiranje: 10 bočica.
Infection of the bowel (Clostridioides difficile infection) is an uncommon side effect that may affect up to 1 in 100 people.
Infekcija crijeva (infekcija s Clostridioides difficile) je manje česta nuspojava koja se može javiti u manje od 1
The mean systemic exposure (AUC) increased 2.2-fold, 5.3-fold, 8.5-fold and 29.8-fold for patients with moderate impairment, severe impairment and ESRD with and without haemodialysis after dosing, respectively compared to the normal control group.
Srednja vrijednost sistemske izloženosti (AUC) povećala se 2,2 puta, 5,3 puta, 8,5 puta odnosno 29,8 puta kod bolesnika s umjerenim oštećenjem, teškim oštećenjem i ESRD-om sa i bez hemodijalize nakon doziranja u odnosu na normalnu kontrolnu skupinu.
This medicine contains 175 mg of sodium (main component of cooking salt) in each vial.
Ovaj lijek sadrži 175 mg natrija (glavni sastojak kuhinjske soli) u jednoj bočici.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS ALUMINIUM/ALUMINIUM BLISTER (TABLETS)
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP ALUMINIJ/ALUMINIJ BLISTER /TABLETE
Peak plasma delafloxacin concentrations are achieved at the end of the 1 hour intravenous infusion.
Vršna koncentracija delafloksacina u plazmi postiže se na kraju intravenske infuzije u trajanju od 1 sata.
Central Nervous System Effects
Učinci na središnji živčani sustav
Patients with toxic shock, neutropenia (neutrophil counts <500 cells/mm3) or severely immunocompromised patients were not included in the studies.
Bolesnici s toksičnim šokom, neutropenijom (broj neutrofila < 500 stanica/mm3) ili teško imunokompromitirani bolesnici nisu bili uključeni u ispitivanja.
• Inflammation of joints, pain in hands or feet, back pain, muscle spasm
• upala zglobova, bolovi u šakama ili stopalima, bolovi u leđima, mišićni grčevi
Intravenous use after reconstitution and dilution
Intravenska primjena nakon rekonstitucije i razrjeđivanja
Unit dose laminated aluminium/aluminium foil blisters.
Blisteri s jediničnom dozom, laminirani aluminij/aluminijska folija.
• If you are allergic to any other fluoroquinolone or quinolone antibacterial medicine.
• ako ste alergični na bilo koji drugi fluorokinolonski ili kinolonski antibakterijski lijek.
• Allergic skin reaction
• alergijska kožna reakcija
The most common adverse drug reactions reported in ABSSSI Phase 2 and 3 studies involving 868 patients exposed to delafloxacin, intravenous or oral formulation, were diarrhoea and nausea (6.91% and 7.83%, respectively) which were mild to moderate in intensity.
Najčešće nuspojave prijavljene u ispitivanjima ABSSSI faze 2 i 3 u koja je bilo uključeno 868 bolesnika izloženih delafloksacinu, intravenskom ili peroralnom obliku, bile su proljev i mučnina (6,91% odnosno 7,83%) koje su bile blage do umjerene težine.
Quofenix will be given to you by a nurse or doctor via an infusion (drip) into a vein.
Quofenix će Vam u venu putem infuzije primijeniti medicinska sestra ili liječnik.
No effects were detected on rat male and female fertility at a level of exposure about 5-fold higher than that observed in humans.
Nisu opaženi učinci na plodnost mužjaka i ženki štakora pri razini izloženosti oko 5 puta većoj nego u ljudi.
Clinically significant gender-related differences in delafloxacin pharmacokinetics have not been observed in healthy subjects or in patients with ABSSSI.
Nisu uočene klinički značajne razlike povezane sa spolom u farmakokinetici delafloksacina u zdravih ispitanika ili bolesnika s ABSSSI-om.
Quofenix is a beige to mottled beige, oblong biconvex tablets, with RX3341 debossed on one side.
Quofenix su duguljaste, bikonveksne tablete bež do pjegavo bež boje, s oznakom RX3341 utisnutom s jedne strane.
This medicinal product contains 175 mg sodium per vial, equivalent to 8.8% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
Ovaj lijek sadrži 175 mg natrija po bočici, što odgovara 8,8% maksimalnog dnevnog unosa od 2 g natrija prema preporukama SZO za odraslu osobu.
This medicinal product contains sulfobutylbetadex sodium.
Ovaj lijek sadrži sulfobutilbetadeksnatrij.
No dose adjustment is necessary in patients with mild to moderate renal impairment (CrCl of ≥30 mL/min).
Nije potrebno prilagođavati dozu u bolesnika s blagim do umjerenim oštećenjem funkcije bubrega (klirens kreatinina, CrCl ≥30 ml/min).
Resistance to fluoroquinolones, including delafloxacin, can occur due to mutations in defined regions of the target bacterial enzymes topoisomerase IV and DNA gyrase referred to as Quinolone-Resistance Determining Regions (QRDRs), or through other resistance mechanisms such as efflux mechanisms.
Rezistencija na fluorokinolone, uključujući delafloksacin, može nastati zbog mutacija na određenim mjestima ciljnih bakterijskih enzima topoizomeraze IV i DNK giraze, takozvanih determinirajućih regija za rezistenciju na kinolone (engl.
Women of childbearing potential have to use effective contraception during treatment with delafloxacin.
Žene u reproduktivnoj dobi moraju koristiti učinkovitu kontracepciju tijekom liječenja delafloksacinom.
The 300-mg IV formulation and 450 mg tablet are bioequivalent with regard to total exposure (AUC).
Intravenska formulacija od 300 mg i tableta od 450 mg su bioekvivalentne s obzirom na ukupnu izloženost (AUC).
• You have a family history of aortic aneurysm or aortic dissection or other risk factors or predisposing conditions (e. g. connective tissue disorders such as Marfan syndrome, or vascular Ehlers-Danlos syndrome, or vascular disorders such as Takayasu arteritis, giant cell arteritis, Behcet's disease, high blood pressure, or known atherosclerosis).
• ako u obiteljskoj povijesti bolesti imate aneurizmu aorte ili disekciju aorte, ili druge rizične faktore ili stanja zbog kojih ste skloniji pojavi aneurizme ili disekcije (npr. poremećaji vezivnog tkiva kao što je Marfanov sindrom ili vaskularni oblik Ehlers-Danlosova sindroma ili vaskularni poremećaji kao što je Takayasuov arteritis, arteritis orijaških stanica, Behcetova bolest, visoki krvni tlak ili poznata ateroskleroza).
Following intravenous use of 300 mg delafloxacin every 12 hours, steady state concentrations are achieved after approximately 3-5 days with about 10% accumulation after multiple administrations.
Nakon intravenske primjene 300 mg delafloksacina svakih 12 sati, koncentracije u stanju dinamičke ravnoteže postignute su približno nakon 3-5 dana, s oko 10% akumulacije nakon višekratne primjene.